Please login to the form below

Not currently logged in
Email:
Password:

Indian pharma company sets sights on European market

Maltese officials announced on February 18 that Indian generics company, Aurobindo, is to extend its operations into Europe with the creation of a new plant in Malta.

Maltese officials announced on February 18 that Indian generics company, Aurobindo, is to extend its operations into Europe with the creation of a new plant in Malta.

The site will be used for laboratory and quality assurance testing needed before the release of their drugs into the European market and is predicted to cost $15 million (10 million euros).

The pharmaceutical industry in Malta currently employs over 800 people within the industry, a number expected to breach 1400 over the next three years, and the new Aurobindo plant will create 120 new jobs.

Minister for Maltese investment, Austin Gatt, said that: "The presence of Aurobindo in Malta is an important milestone in the success of the pharmaceutical sector in our country."

Aurobindo, who Gatt referred to as a "role-model company with a global reputation", is one of the world's top five manufacturers of semi synthetic penicillins.

With 26 pending Abbreviated New Drug Applications (ANDA) in Europe, Aurobindo Pharma chose Malta for its new plant because of factors such as reduced income tax and access/transit links to the European market.

"We have the determination to succeed in a bigger way through our ambitious Malta project," said Aurobindo. "We are happy to contribute to the Maltese industry and economy and we are very thankful for the nation's encouragement hospitality and support."

21st February 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics